Want to see PDSB full AI Analyst Report?
PDSB Stock Chart & Stats
$1.31
-$0.09(-5.36%)
At close: 4:00 PM EST
$1.31
-$0.09(-5.36%)
Day’s Range― - ―
52-Week Range$0.51 - $1.55
Previous CloseN/A
Volume197.50K
Average Volume (3M)526.87K
Market Cap
$41.10M
Enterprise Value$27.78
Total Cash (Recent Filing)$21.66M
Total Debt (Recent Filing)$15.86M
Price to Earnings (P/E)―
Beta2.88
Next Earnings
Aug 18, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding55,921,806
10 Day Avg. Volume342,508
30 Day Avg. Volume526,865
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.86
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside1045.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Protocol Amendment Speeds ReadoutChanging VERSATILE‑003 to include PFS as an interim co‑primary endpoint and cutting enrollment by ~28.6% materially shortens trial duration and lowers per‑trial cash needs. This structurally accelerates clinical de‑risking and reduces near‑term financing pressure versus the original design.
Extended Patent ProtectionPatents extending PDS0101 protection into the 2040s provide a durable barrier to entry, lengthening the potential commercial window. Long patent life supports licensing, partnership economics and investor confidence by protecting future revenue streams once approved.
Manufacturing And CMC ReadinessAn established Versamune commercial manufacturing process and completed scale‑up reduce execution risk at approval and shorten time to market. CMC readiness is a lasting operational advantage, lowering commercialization uncertainty and supporting durable supply and margin predictability.
Bears Say
Pre-revenue, Persistent LossesThe company remains pre‑revenue with recurring, sizable losses and a sharp TTM deterioration, a structural constraint on self‑funding. Persistent negative cash flows necessitate repeated financing, increasing dilution risk and limiting strategic optionality over the medium term.
High‑cost Refinancing With Dilution RiskReplacing secured convertible debentures with a one‑year $6M note at 10% and attached warrants raises effective funding costs and embeds potential dilution. Such high‑cost, short‑dated financing and conditional conversion features strain future cash flow and restrict capital flexibility.
Regulatory And Competitive RelianceAccelerated approval via PFS still leaves OS required for full approval, necessitating longer follow‑up or additional trials. Combined with competition (other Phase III programs) and reliance on an anti‑PD‑1 partner, this creates structural execution and market risk for durable commercialization.
PDS Biotechnology News
PDSB FAQ
What was Pds Biotechnology’s price range in the past 12 months?
Pds Biotechnology lowest stock price was $0.51 and its highest was $1.55 in the past 12 months.
What is Pds Biotechnology’s market cap?
Pds Biotechnology’s market cap is $41.10M.
When is Pds Biotechnology’s upcoming earnings report date?
Pds Biotechnology’s upcoming earnings report date is Aug 18, 2026 which is in 30 days.
How were Pds Biotechnology’s earnings last quarter?
Pds Biotechnology released its earnings results on May 13, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.01.
Is Pds Biotechnology overvalued?
According to Wall Street analysts Pds Biotechnology’s price is currently Undervalued.
Does Pds Biotechnology pay dividends?
Pds Biotechnology does not currently pay dividends.
What is Pds Biotechnology’s EPS estimate?
Pds Biotechnology’s EPS estimate is -0.13.
How many shares outstanding does Pds Biotechnology have?
Pds Biotechnology has 55,921,806 shares outstanding.
What happened to Pds Biotechnology’s price movement after its last earnings report?
Pds Biotechnology reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went up 20.909%.
Which hedge fund is a major shareholder of Pds Biotechnology?
Currently, no hedge funds are holding shares in PDSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PDS Biotechnology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (1045.04% Upside)
$15.00 (1045.04% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.83%
12-Months-Change
Fundamentals
Return on Equity
-346.03%
Trailing 12-Months
Asset Growth
-47.56%
Trailing 12-Months
Company Description
Pds Biotechnology
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
PDSB Stock 12 Month Forecast
Average Price Target
$15.00
▲(1045.04% Upside)
Technical Analysis
Ownership Overview
1.51%
Insiders
3.89% Mutual Funds
0.34% Other Institutional Investors
91.02% Public Companies and
Individual Investors